test3

Find A Clinical Trial

Disease Type: Lung

Trial ID TAK-981-1502
Sponsor ID Takeda Oncology

Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

1 Location
Trial ID M20-111
Sponsor ID AbbVie

“A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors”

1 Location
Trial ID CAR107
Sponsor ID Chipscreen

A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung Cancer

1 Location
Trial ID 61186372PANSC2002
Sponsor ID PolyDamas

“A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer”

1 Location
Trial ID 61186372PANSC2001
Sponsor ID MetalMark

A Phase 1/2 Open-label Platform Study to Evaluate the Safety and Efficacy of Multiple Amivantamab-based Therapeutic Combinations in Participants with Advanced, Unresectable Lung Cancer (LC)

1 Location
Trial ID IO102-IO103-022
Sponsor ID IO Biotech

A Phase 2 Multi Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab as First-Line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, or Metastatic Urothelial Bladder Cancer

Trial ID FF10832-PEM-201
Sponsor ID KEYNOTE B-57

A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

Trial ID D926NC00001
Sponsor ID AVANZAR

“A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)”

1 Location
Trial ID D9075C00001
Sponsor ID PACIFIC-8

“A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)”

3 Locations
Trial ID D9072C00001
Sponsor ID Scope-D1

“A Phase 1/2a, Open-label, Multicentre Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients with Non-Small Cell and Small Cell Lung Cancer – SCope-D1”

1 Location